In the last few decades, incredible strides have been made in genome typing and precision medicine technology. What used to cost hundreds of thousands of dollars is now available for $100, opening up the biotech world to tons of new research and treatment opportunities. But the vast majority of clinical trials fail, and biotechs are very risky investments.